Zadnja posodobitev :
28/04/2024
Antiemetik   Palonosetron hydrochloride  
Brizgalka
Stabilnost raztopine Stabilnost mešanice Faktorji, ki vplivajo na stabilnost Kompatibilnost Način aplikacije Viri Pdf
   Kemična formula  

Lastniško ime   Lastniško ime     

Sestava pomožnih snovi je med paralelami lahko različna

Aloxi Avstrija, Belgija, Danska, Finska, Grčija, Irska, Islandija, Italija, Japonska, Kanada, Luksemburg, Madžarska, Malezija, Nemčija, Nizozemska, Norveška, Poljska, Portugalska, Romunija, Španija, Švedska, Švica, Turčija, Velika Britanija, Združene države Amerike
Chepatron Indija
Cinvex Turčija
Factoket Mehika
Lotisa Turčija
Onicit Čile, Ekvador, Italija, Kolumbija, Peru
Palohalt Čile, Peru
Paloject Turčija
Palonosetron Belgija, Čile, Ekvador, Francija, Nemčija, Španija, Švica, Velika Britanija
Palostar Indija
Palzen Indija
Vinaltro Mehika
Viqet Mehika
Vonaxi Turčija
Viri   Brizgalka   Viri : Palonosetron hydrochloride  
Tip Objava
1932 časopis Trissel LA, Zhang Y.
Compatibility and stability of Aloxi (palonosetron hydrochloride) admixed with dexamethasone sodium phosphate.
Int J Pharm Compound 2004 ; 8,5: 398-403.
1936 časopis Trissel LA, Xu QA.
Physical and chemical stability of palonosetron HCl in 4 infusion solusions.
Ann Pharmacotherapy 2004 ; 38: 1608-1611.
1940 časopis Xu QA, Trissel LA.
Stability of palonosetron hydrochloride with paclitaxel and docetaxel during simulated Y-site administration.
Am J Health-Syst Pharm 2004 ; 61: 1596-1598.
1950 časopis Trissel LA, Yanping Z.
Physical and chemical stability of palonosetron HCl with cisplatin, carboplatin and oxaliplatin during simulated Y-site administration.
J Oncol Pharm Practice 2004 ; 10: 191-195.
1955 časopis Trissel LA, Zhang Y.
Palonosetron HCl compatibility and stability with doxorubicin HCl and epirubicin HCl during simulated Y-site administration.
Ann Pharmacotherapy 2005 ; 39: 280-283.
1975 časopis Trissel LA, Xu QA.
Physical and chemical stability of palonosetron hydrochloride with lorazepam and midazolam hydrochloride during simulated Y-site administration.
Int J Pharm Compound 2005 ; 9, 3: 235-237.
1976 časopis Trissel LA, Xu QA.
Physical and chemical stability of palonosetron hydrochloride with topotecan hydrochloride and irinotecan hydrochloride during simulated Y-site administration.
Int J Pharm Compound 2005 ; 9, 3: 238-241.
2009 časopis Trissel LA, Zhang Y.
Physical and chemical stability of palonosetron hydrochloride with fluorouracil and with gemcitabine hydrochloride during simulated Y-site administration.
Int J Pharm Compound 2005 ; 2005, 9, 4: 320-322.
2016 časopis Xu QA, Trissel LA.
Compatibility of palonosetron with cyclophosphamide and with ifosfamide during Y-site administration.
Am J Health-Syst Pharm 2005 ; 62: 1998-2000.
2107 časopis Trissel LA, Zhang Y, Xu QA.
Physical and chemical stability of palonosetron hydrochloride with dacarbazine and with methylprednisolone sodium succinate during simulated Y-site administration.
Int J Pharm Compound 2006 ; 10: 234-236.
2179 časopis Trusley C, Ben M, Kupiec TC, Trissel LA.
Physical and chemical stability of palonosetron with metoclopramide and promethazine during simulated Y-site administration.
Int J Pharm Compound 2007 ; 11, 1: 82-85.
2196 časopis Trissel LA, Trusley C, Ben M, Kupiec TC.
Physical and chemical stability of palonosetron hydrochloride with five opiate agonists during Y-site administration.
Am J Health-Syst Pharm 2007 ; 64, 11: 1209-1213.
2214 časopis Ben M, Trusley C,Kupiec T.C, Trissel L.A.
Palonosetron hydrochloride compatibility and stability with three beta-lactam antibiotics during simulated Y-site administration.
Int J Pharm Compound 2007 ; 11, 6: 520-524.
2227 časopis Trusley C, Ben M, Kupiec TC, Trissel LA.
Compatibility and stability of palonosetron hydrochloride with four neuromuscular blocking agents during simulated Y-site administration.
Int J Pharm Compound 2008 ; 12, 2: 156-160.
2228 časopis Kupiec T, Ben M, Trusley C, Trissel LA.
Compatibility and stability of palonosetron hydrochloride with gentamicin, metronidazole, or vancomycin during simulated Y-site administration.
Int J Pharm Compound 2008 ; 12,2: 170-173.
2279 časopis Kupiec T, Trusley C, Ben M, Trissel LA.
Physical and chemical stability of palonosetron hydrochloride with five common parenteral drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2008 ; 65, 18: 1735-1759.
2281 časopis Ben M, Kupiec T, Trusley C, Trisel LA.
Compatibility and stability of palonosetron hydrochloride with lactated Ringer's, Hetastarch in lactated electrolyte, an mannitol injections during simulated Y-site administration.
Int J Pharm Compound 2008 ; 12, 5: 460-462.
2286 časopis Ben M, Trusley C, Kupiec TC, Trissel LA.
Physical and chemical stability of palonosetron hydrochloride with glycopyrrolate and neostigmine during simulated Y-site administration.
Int J Pharm Compound 2008 ; 12, 4: 368-371.
2312 časopis Trissel L.A, Trusley C, Kupiec T.C, Ben M.
Compatibility and stability of palonosetron hydrochloride and propofol during simulated Y-site administration.
Int J Pharm Compound 2009 ; 13, 1: 78-80.
3459 časopis Sun S, Schaller J, Placek J, Duersch B.
Compatibility of intravenous fosaprepitant with intravenous 5-HT3 antagonists and corticosteroids.
Cancer Chemother Pharmacol 2013 ; 72: 509-513.
3928 časopis Wu G, Yeung S, Chen F.
Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Intravenous Palonosetron Hydrochloride.
Int J Pharm Compound 2017 ; 21, 1: 76-82.
3981 časopis He G, Zeng F, Lei K, Xia S, Deng L, Zhang C, Liu D.
Compatibility of dexamethasone sodium phosphate with 5-HT3 receptor antagonists in infusion solutions: a comprehensive study
EJHP 2017 ;24:162?166
4062 časopis Wu George, Powers Dan, Yeung S, Chen F, Neelon K.
Compatibility and stability of VARUBI (Rolapitant) injectable emulsion admixed with intravenous palonosetron hydrochloride injection and dexamethasone sodium phosphate injection.
Int J Pharm Compound 2018 ;22,1:76-85
4310 časopis Mizuta N, Nakagawa T, Yamamoto K, Nishioka T, Kume M, Makimoto H, Yano I, Minami H, Hiral M.
Compatibility and Stability of Nab-Paclitaxel in Combination with Other Drugs.
Kaohsiung J Med Sci 2017 ; 63, 1: E9-E16.

  Mentions Légales